Abstract
Our results suggest that circulating NPM mutations DNA assay serves as a complementary tool to the routine investigative protocol of NPM-mutated leukemia. By quantifying mutated DNA circulating freely in the plasma, this study demonstrates a less-invasive method to track disease burden that correlates strongly with traditional diagnostic markers.
Introduction
Acute Myeloid Leukemia (AML) monitoring traditionally relies on bone marrow (BM) aspirates. While effective, these biopsies are invasive and provide only localized snapshots of the disease. The Nucleophosmin (NPM) gene is mutated in approximately 30% of AML cases, making it a critical marker for prognosis and monitoring minimal residual disease (MRD). This study investigates whether cell-free DNA (cfDNA) in plasma can serve as a reliable, non-invasive proxy for monitoring disease status.
Methods
The study analyzed 100 newly diagnosed AML patients. Researchers identified those with NPM mutations using RT-PCR and sequencing. For mutation-positive cases, a real-time quantitative PCR (qRT-PCR) assay was developed to target "NPM mutation A," the most common variant. A plasmid vector containing the target mutation was used to establish a standard curve for calculating DNA copies per milliliter of plasma. These levels were then correlated with clinical parameters such as white blood cell (WBC) counts and bone marrow blast percentages.
Results and Discussion
Of the 100 patients, 37% carried the NPM Type A mutation. The plasma assay demonstrated high sensitivity, identifying 37 positive cases compared to 35 identified in the cellular fraction of peripheral blood.
Subtype Variability
Circulating DNA levels varied significantly across FAB subtypes. Patients with the M5 (monocytic) subtype exhibited the highest levels of mutated DNA, potentially reflecting differences in cellular proliferation or apoptosis rates between subtypes.
Clinical Correlations
A key finding was the strong association between plasma NPM mut.A levels and disease severity. High levels of circulating mutated DNA ($0.35 \times 10^8$ to $6.0 \times 10^8$ copies/ml) were significantly correlated with higher bone marrow blast percentages ($>70\%$) and elevated white blood cell counts ($>40 \times 10^9/L$).
Conclusion
The quantitative detection of plasma NPM mutations offers a promising, less-invasive alternative to traditional bone marrow monitoring. While the study is limited by its sample size and focus on a single mutation variant, the strong correlation with clinical markers suggests that "liquid biopsies" could play a vital role in future AML management. Further longitudinal studies are required to validate this assay for monitoring treatment response and early relapse detection.
Summary updated